Form 4 holding
10%+ Owner
Ernexa Therapeutics Inc.
- Security class
- Common Stock
- Shares / value
- 6,779,440
- Estimated value
- $3,389,720
- Report date
- 10 Feb 2026
- Price
- $0.5000
- Ownership
- Direct
Charles Cherington
Insider Reports History
- Reporting-owner location
- Cambridge, MA
- Latest reporting-owner signature
- /s/ Charles Cherington
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Charles Cherington
Form 4 holding
10%+ Owner
Comera Life Sciences Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 5,813,650
- Estimated value
- $411,606
- Report date
- 11 Sep 2023
- Price
- $0.0708
- Ownership
- Direct
Form 4 holding
10%+ Owner
Comera Life Sciences Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 1,268,761
- Estimated value
- $89,828
- Report date
- 11 Sep 2023
- Price
- $0.0708
- Ownership
- By LLC
Form 4 holding
10%+ Owner
Comera Life Sciences Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 95,328
- Estimated value
- $6,749
- Report date
- 11 Sep 2023
- Price
- $0.0708
- Ownership
- By trust
Form 4 holding
10%+ Owner
Comera Life Sciences Holdings, Inc.
- Security class
- Warrants to Purchase Common Stock
- Shares / value
- 20,650,908
- Estimated value
- Report date
- 29 Dec 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Ernexa Therapeutics Inc.
- Security class
- Warrants to Purchase Common Stock
- Shares / value
- 4,000,000
- Estimated value
- Report date
- 10 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Comera Life Sciences Holdings, Inc.
- Security class
- Series A Convertible Perpetual Preferred Stock
- Shares / value
- 3,896
- Estimated value
- Report date
- 27 Dec 2023
- Price
- Ownership
- By LLC
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Comera Life Sciences Holdings, Inc.
- Security class
- 12.0% Senior Secured Convertible Notes
- Shares / value
- $567,900
- Estimated value
- Report date
- 29 Dec 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Charles Cherington
4
ERNA
Ernexa Therapeutics Inc.
- Report period
- 10 Feb 2026
- Transactions
- 2
- Transaction value
- +$2,000,000
- Accepted by SEC
- 17 Feb 2026, 21:14
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Ernexa Therapeutics Inc.
- Report period
- 09 Jun 2025
- Transactions
- 1
- Transaction value
- +$2,221,826
- Accepted by SEC
- 11 Jun 2025, 20:34
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Eterna Therapeutics Inc.
- Report period
- 02 Apr 2025
- Transactions
- 1
- Transaction value
- +$394,174
- Accepted by SEC
- 04 Apr 2025, 10:54
- Role
- 10%+ Owner
- Next action
- Open filing details
4/A
ERNA
Ernexa Therapeutics Inc.
- Report period
- 24 Sep 2024
- Transactions
- 10
- Transaction value
- -$6,540,000
- Accepted by SEC
- 07 May 2025, 11:48
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Eterna Therapeutics Inc.
- Report period
- 23 Sep 2024
- Transactions
- 17
- Transaction value
- -$4,890,227
- Accepted by SEC
- 05 Nov 2024, 12:42
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 27 Dec 2023
- Transactions
- 3
- Transaction value
- +$1,948,332,900
- Accepted by SEC
- 03 Jan 2024, 20:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Eterna Therapeutics Inc.
- Report period
- 14 Dec 2023
- Transactions
- 6
- Transaction value
- +$3,390,747
- Accepted by SEC
- 20 Dec 2023, 10:05
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 11 Sep 2023
- Transactions
- 2
- Transaction value
- +$1,049,897
- Accepted by SEC
- 11 Sep 2023, 20:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 31 Jul 2023
- Transactions
- 2
- Transaction value
- +$450,044
- Accepted by SEC
- 25 Aug 2023, 19:33
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Eterna Therapeutics Inc.
- Report period
- 13 Jul 2023
- Transactions
- 2
- Transaction value
- +$3,588,462
- Accepted by SEC
- 25 Aug 2023, 19:34
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 04 Jan 2023
- Transactions
- 2
- Transaction value
- +$1,100,000
- Accepted by SEC
- 06 Jan 2023, 15:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Eterna Therapeutics Inc.
- Report period
- 02 Dec 2022
- Transactions
- 2
- Transaction value
- +$923,999
- Accepted by SEC
- 06 Dec 2022, 20:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 20 Oct 2022
- Transactions
- 2
- Transaction value
- +$23,680
- Accepted by SEC
- 24 Oct 2022, 16:03
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 14 Oct 2022
- Transactions
- 2
- Transaction value
- +$32,167
- Accepted by SEC
- 18 Oct 2022, 16:04
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 13 Oct 2022
- Transactions
- 1
- Transaction value
- +$17,387
- Accepted by SEC
- 14 Oct 2022, 16:03
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 29 Sep 2022
- Transactions
- 1
- Transaction value
- +$33,477
- Accepted by SEC
- 30 Sep 2022, 16:04
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Comera Life Sciences Holdings, Inc.
- Report period
- 27 Sep 2022
- Transactions
- 1
- Transaction value
- +$20,221
- Accepted by SEC
- 29 Sep 2022, 16:02
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Brooklyn ImmunoTherapeutics, Inc.
- Report period
- 01 Aug 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Aug 2022, 20:01
- Role
- Director
- Next action
- Open filing details
3
Comera Life Sciences Holdings, Inc.
- Report period
- 19 May 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 14 Sep 2022, 20:04
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ERNA
Brooklyn ImmunoTherapeutics, Inc.
- Report period
- 08 Dec 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 10 Dec 2021, 20:00
- Role
- Director
- Next action
- Open filing details
3
Beard Energy Transition Acquisition Corp.
- Report period
- 23 Nov 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 23 Nov 2021, 20:10
- Role
- Director
- Next action
- Open filing details
4
ERNA
Brooklyn ImmunoTherapeutics, Inc.
- Report period
- 16 Jun 2021
- Transactions
- 3
- Transaction value
- -$6,296,568
- Accepted by SEC
- 21 Jun 2021, 18:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details